BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York on May 14 – 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894890 (State or Other Ju ...

Exhibit 99.1 CORMEDIX INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – May 9, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: ...

BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2024, before the market opens on Thursday, May 9, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, May 9th @ 8:30am ETDomestic:1-888-886-7786Internationa ...

CorMedix (CRMD) closed the last trading session at $5.52, gaining 33.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13 indicates a 135.5% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $4.55. While the lowest estimate of $9 indicates a 63% increase from the current price level, the most optimistic analyst expects the sto ...

BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for U.S. inpatient use. DefenCath (taurolidine and heparin) is approved by the U.S. Food and Drug Administration (FDA) to reduce the incidence of catheter-related bloodstream ...

CRMD股价表现 - CorMedix (CRMD)股价在过去四周上涨了35.4%，收盘价为$5.28[1] - 根据华尔街分析师的短期价格目标，平均估值为$13，显示潜在上涨空间为146.2%[2] CRMD公司盈利展望 - 分析师对CRMD公司未来盈利表现的乐观态度加强了对其潜在上涨的看法[4] - 盈利预期修订的积极趋势被证明是预测上涨的有力指标[9] CRMD股价走势分析 - 分析师对股价走势的高度一致性，即低标准差，表明他们对股价运动的方向和幅度有很高的一致性[7]

BERKELEY HEIGHTS, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath® (taurolidine and heparin). CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and Antifungal Dru ...

财务数据和关键指标变化 - 2023年第四季度净亏损约1480万美元,每股亏损0.26美元,而2022年同期为820万美元,每股亏损0.20美元,主要由于2023年市场研究和产品上市前活动成本增加,以及人员费用增加所致 [25][26] - 2023年全年运营费用为4900万美元,较2022年增加60%,其中研发费用增加23%至1320万美元,销售及一般管理费用增加79%至3580万美元 [27][28] - 2023年全年经营活动净现金流出3840万美元,较2022年增加 [28] - 截至2023年12月31日,公司现金及现金等价物为7600万美元,预计2024年每季度运营费用将在1500万至1800万美元之间 [29][30] 各条业务线数据和关键指标变化 - 公司计划于2024年4月15日开始在医院内部市场推广DefenCath,预计前两个季度的使用量会较缓慢,因为医院需要经历3-9个月的药品和治疗委员会(P&T)审核流程 [18][37][38] - 在门诊市场,公司正与大型和中型透析运营商进行积极沟通,预计这些讨论将在未来几个月内取得进展 [19][38][39] 各个市场数据和关键指标变化 - 公司正在积极与医院和医疗系统进行P&T会议,预计2季度会有更多会议安排,但时间进度存在不确定性 [37][38] - 在门诊市场,公司预计初期会先针对付费服务患者,然后逐步扩展到其他患者群体 [38][39] 公司战略和发展方向及行业竞争 - 公司正在准备向FDA提交扩大DefenCath适应症的申请,如果获批,可以快速启动相关临床试验 [40][41] - 公司目前有约30名销售人员,未来可能增加至45-50人,覆盖医院和门诊两个市场 [46][47] - 公司对未来政治格局变化对CMS报销政策的影响保持谨慎态度,但目前没有看到会有重大变化 [48] 管理层对经营环境和未来前景的评论 - 公司有望在2024年底前实现盈亏平衡,但前提是达成内部预测的销量、价格和报销目标 [19][30] - 公司有充足的现金资源支持商业化进程,如果进度低于预期需要更多资金,也有多种融资渠道可选 [19][29][30] - 公司正积极准备商业化发售,包括建立销售和医疗团队,并正在增加产品库存 [16][20] 问答环节重要的提问和回答 问题1 **Jason Butler 提问** 询问医院P&T委员会审核进度及初期使用情况 [37][38][39] **Joe Todisco 回答** 公司已安排部分P&T会议,预计2季度会有更多,但时间进度存在不确定性。在医院内部市场,预计使用量会较缓慢增长,而门诊市场可能会有较大波动 [38][39] 问题2 **Anish Nikhanj 提问** 询问商业团队构成及政治环境对CMS报销政策的影响 [45][46][47][48] **Joe Todisco 回答** 公司采用统一的销售团队覆盖医院和门诊市场,目前有约30人,未来可能增加至45-50人。政治环境变化对CMS政策影响存在不确定性,但短期内预计不会有重大变化 [46][47][48] 问题3 **Les Sulewski 提问** 询问分销渠道、库存水平、3ml和5ml剂型比例以及制造成本转为专利成本的时间 [51][52][53][54][55] **Joe Todisco 回答** 医院内部使用通过专业分销商,门诊可能直接供货或通过分销商。公司计划只推广3ml剂型,制造成本转为专利成本的时间取决于产品需求增长速度 [52][53][54][55]

公司业绩 - 公司宣布了2023年第四季度和全年财务业绩，并更新了业务进展[1] - 公司最近的重要亮点包括获得FDA批准新药DefenCath，以及获得Medicare & Medicaid Services的TDAPA认可[2] 商业推出准备 - 公司已加大商业推出准备工作，包括招聘和培训销售和医务人员，并计划在2024年4月开始在院内推出产品[3] - 公司正加紧生产库存以满足预期需求，并计划在4月向FDA提交DefenCath NDA的补充申请[4]